These compounds have shown promise in dissolving aggregates formed by structurally destabilized p53 mutations like R175H and Y220C, potentially restoring some normal p53 functions and slowing cancer progression.606 However, in the case of mutations such as R248Q, which primarily impact p53’s DNA-binding ability rather than its structural integrity, BAY compounds may inadvertently promote further aggregation.607 This emphasizes the critical need for careful application, highlighting the significance of adapting treatment strategies to the specific p53 mutation identified in the tumor.603,608. This evidence concerns the gene TP53 and cancer.